NATALIE SLOAN: Open Payments
NPI 1710433131 · RANCHO MIRAGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,751 in 72 payments from 12 companies in 2025. Trend: 2023 $1,449 · 2024 $2,001 · 2025 $1,751
Food & beverage: $1,751
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 13 | $460 |
| Janssen Biotech, Inc. | 12 | $374 |
| ABBVIE INC. | 21 | $357 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $175 |
| Celltrion USA Inc. | 5 | $104 |
| Daiichi Sankyo Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $66 |
| Braintree Laboratories, Inc. | 2 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Intercept Pharmaceuticals, Inc. | 1 | $25 |
Products named: REZDIFFRA, TREMFYA, RINVOQ, XIFAXAN, VEGZELMA, LINZESS, INJECTAFER, EOHILIA.
Industry payments across CA — which companies pay providers there.
